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BACKGROUND. The strength of the association between intensive care unit (ICU)-acquired nosocomial infections (NIs) and mortality 
might differ according to the methodological approach taken. 
OBJECTIVE. To assess the association between ICU-acquired NIs and mortality using the concept of population-attributable fraction 
(PAF) for patient deaths caused by ICU-acquired NIs in a large cohort of critically ill patients. 
SETTING. Eleven ICUs of a French university hospital. 
DESIGN. We analyzed surveillance data on ICU-acquired NIs collected prospectively during the period from 1995 through 2003. The 
primary outcome was mortality from ICU-acquired NI stratified by site of infection. A matched-pair, case-control study was performed. 
Each patient who died before ICU discharge was defined as a case patient, and each patient who survived to ICU discharge was defined 
as a control patient. The PAF was calculated after adjustment for confounders by use of conditional logistic regression analysis. 
RESULTS. Among 8,068 ICU patients, a total of 1,725 deceased patients were successfully matched with 1,725 control patients. The 
adjusted PAF due to ICU-acquired NI for patients who died before ICU discharge was 14.6% (95% confidence interval [CI], 14.4%—14.8%). 
Stratified by the type of infection, the PAF was 6.1% (95% CI, 5.7%-6.5%) for pulmonary infection, 3.2% (95% CI, 2.8%-3.5%) for 
central venous catheter infection, 1.7% (95% CI, 0.9%-2.5%) for bloodstream infection, and 0.0% (95% CI, -0.4% to 0.4%) for urinary 
tract infection. 
CONCLUSIONS. ICU-acquired NI had an important effect on mortality. However, the statistical association between ICU-acquired NI 
and mortality tended to be less pronounced in findings based on the PAF than in study findings based on estimates of relative risk. 
Therefore, the choice of methods does matter when the burden of NI needs to be assessed. 
Infect Control Hosp Epidemiol 2010; 31:388-394 
Intensive care unit (ICU)-acquired nosocomial infections of patients that would not have died if exposure had not 
(NIs) are thought to increase patient mortality.13 However, occurred."13 Various epidemiologic methods can be used to 
the magnitude of this effect remains controversial and de- evaluate the PAF, including expert assessment of case series, 
pends on study design, type of infection, and target popu- In contrast to the rich literature available in the field of 
lation.4"12 Previous investigations have reported mortality es- chronic disease epidemiology, controlled studies aiming to 
timates related to ICU-acquired NI of 4%-50%.1"6,9'10 The determine the proportion of hospital deaths attributable to 
corresponding relative risks of death due to ICU-acquired NI NI are both rare and insufficient for the calculation of sta-
were 1.4-4.0, and the corresponding odds ratios were 1.7- ble estimates.1415 Furthermore, several methodological issues 
3.2.3,4'8"12 have to be considered, since the causal relationship between 
The population-attributable fraction (PAF) of death is a exposure (to a pathogen that causes NI) and death can be 
well-known public health concept, defined as "the fraction jeopardized by multiple confounders and biases, such as se-
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TABLE 1. Characteristics of Intensive Care Unit Patients Excluded from and Included in the Study 
Characteristic 
Male sex 
Age, years 
Length of stay, days 
Died before discharge 
Immunocompromised 
SAPS II 
Excluded 
patients 
(n = 4,178 
[34.1%]) 
2,453 (58.7) 
57.4 ± 19.3 
5.2 ± 4.5 
363 (8.7) 
448 (10.7) 
30.6 ± 15.2 
Unexposed 
patients 
(n = 6,391 
[52.2%]) 
4,193 (65.6) 
58.5 ± 17.5 
7.8 ± 6.0 
1,279 (20.0) 
1,112 (17.4) 
39.3 ± 18.1 
p . 
.001 
.005 
.001 
.001 
.001 
.001 
Included patients 
Exposed 
patients 
(« = 1,677 
[13.7%]) 
1,071 (63.9) 
58.7 ± 17.6 
15.5 ± 7.6 
556 (33.2) 
245 (14.6) 
43.1 ± 17.0 
P" 
.001 
.025 
.001 
.001 
.001 
.001 
All included 
patients 
(n = 8,068 
[65.9%]) 
5,264 (65.2) 
58.5 ± 17.5 
9.4 ± 7.1 
1,835 (22.7) 
1,357 (16.8) 
40.1 ± 17.9 
pa 
.001 
.002 
.001 
.001 
.001 
.001 
N O T E . Values are expressed as no. (%) for qualitative variables and as mean ± SD for quantitative variables. SAPS II, Simplified 
Acute Physiology Score; SD, standard deviation. 
" The x2 t e s t w a s u s ed to compare categorical variables, and the Student t test was used to compare continuous variables. 
verity of the underlying illness and the infection type.1,210 In 
addition, small sample size can be associated with statistical 
power inadequate to generate meaningful PAF estimates.16 
The objective of this case-control study was to provide 
accurate estimates of the adjusted PAF of ICU-acquired NI 
in a large cohort of critically ill patients. 
M E T H O D S 
Patients and Setting 
Our study was based on data collected prospectively by a 
nosocomial infection surveillance network1718 during the pe-
riod from January 1, 1995, through December 31, 2003, from 
11 adult ICUs at the University Hospital of Lyon, France. 
Design 
A case-control study with individual pair matching was un-
dertaken according to the approach proposed by Bruzzi et 
al.19 Case patients were patients who died before ICU dis-
charge, whereas control patients were patients who survived 
to discharge. For each case patient, 1 control patient from 
the same ICU was selected and matched according to the 
following criteria: sex, age (stratified into 7 age groups), and 
year of admission. If multiple control patients were available, 
the one with the date of admission closest to that of the case 
patient was retained. The following variables were collected 
and analyzed as potential confounders: Simplified Acute 
Physiology Score at ICU admission, immunodepression, and 
type of condition at admission (medical, surgical, or 
trauma).20'21 All variables were collected according to the cri- S t a t i s t i c a l Analysis 
teria of a standardized and validated protocol, established by 
an ICU surveillance network in France.1718 
acquired NI was defined as infection that occurred at least 
48 hours after admission to the ICU, determined on the basis 
of clinical and microbiological criteria.17,18'22,23 The 4 types of 
ICU-acquired NI considered for analysis were pulmonary in-
fections, central venous catheter (CVC) infections, urinary 
tract infections (UTIs), and bloodstream infections (BSIs). 
For each patient, only the first infection in any of these 4 
sites was analyzed. We calculated the incidence of ICU-ac-
quired NI as the number of cases of ICU-acquired NI per 
100 patients per period (period was the duration of the stay 
in the hospital). 
We stratified analysis by type of infection and number of 
infected sites. To further explore the complex association be-
tween ICU-acquired NI and death in the ICU, we fitted 5 
different models, stratified by type of infection and number 
of infected sites (see Appendix, Table A). The first model 
included any type of infection during the ICU stay that oc-
curred in any of the 4 body sites. For this model, only the 
first ICU-acquired NI for each patient was taken into account. 
The other 4 subgroup models dealt with each type of ICU-
acquired NI separately. For each of these models, patients 
with ICU-acquired NI at only 1 specific, primary site were 
compared with a patient group without ICU-acquired NI (no 
infection), with a group who had at least 1 ICU-acquired NI 
at the primary site with coinfection at 1 or more of the 3 
other sites, and finally with a group of patients who had ICU-
acquired NI at 1 or more of the 3 other sites but no infection 
at the primary site. 
Definitions of ICU-Acquired NI 
We defined various risk levels of patient death before dis-
charge from the ICU according to exposures to ICU-acquired 
NI. Exposure was defined as the presence of at least one ICU-
acquired NI in a given patient, ascertained according to a 
standardized protocol and established guidelines.17,18'22'23 ICU-
We used the McNemar test to compare proportions and the 
paired Student t test to compare means. Calculation of the 
crude PAF of deaths related to ICU-acquired NI was based 
on the following equation using the relative odds of death 
(ROD):24 
PAF = CFB x [(ROD - l)/ROD] , 
where CF£ is the case patient fraction exposed to ICU-ac-
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quired NI and [(ROD - l)/ROD] is the etiological fraction 
of attributable risk for case patients to be exposed at least 
once to ICU-acquired NI. 
To perform multivariate analysis and generate an adjusted 
estimate of the PAF of death due to ICU-acquired NI, we 
determined the PAF for multiple levels of exposure. An ex-
posure was defined as, for example, the presence in the ICU 
of 1 patient with 1 pulmonary infection or 1 patient with 1 
UTI. Then, to assess the sum of category-specific attributable 
fractions, we used the following equation:25"27 
PAF = 1 - [CF^l/ROD,) 
+ CFE2(l/ROD2) + CFE3(l/ROD3)] , 
where CFEI, CFE2, and CFE3 are the exposure incidence in case 
patients according to the different levels of exposure. The 
quantities ROD1( ROD2, and ROD3 are the different RODs 
according to the levels of exposure and type of ICU-acquired 
NI (see above). 
We computed the adjusted RODs and 95% confidence in-
tervals (CIs) with conditional multiple logistic regression 
models.28,29 We incorporated different terms for the specific 
ICU-acquired NI in the 5 models corresponding to different 
polytomous "risk levels" of infection (see Appendix, Table 
A). All covariates that reached a statistical threshold (P< 
.10) in univariate analysis were included in a multivariable 
model. All analyses were performed with SPSS for Windows, 
version 10.1 (SPSS). 
RESULTS 
A total of 12,246 patients in 11 ICUs were registered in the 
surveillance network during the study period. We excluded 
all patients with incomplete data, leaving 8,068 potentially 
eligible patients for analysis. The main reason for exclusion 
was that data were missing for reliable assessment of the 
presence or absence of ICU-acquired NI. The distribution of 
missing data was as follows: 24 patients (0.2%) with missing 
information on possible pulmonary infection, 4,137 patients 
(33.8%) without information on CVC infection, 56 patients 
(0.5%) without information on UTI, and 28 patients (0.2%) 
without information on BSI. In total, data were missing for 
4,178 patients (34.1%). Table 1 compares characteristics be-
tween included and excluded patients. 
Among the 8,068 patients included in the study, the total 
incidence of ICU-acquired NI was 20.8% during the study 
period (annual range, 16.7% [in 2003] to 25.6% [in 1996]; 
P< .001). The range in total incidence among the different 
ICUs was 6.3%-29.6% (P<.001). The mean annual inci-
dence was 8.0% for pulmonary infection, 7.9% for CVC in-
fection, 7.6% for UTI, and 3.3% for BSI. During the study 
period, 1,835 patients (22.7%) died before ICU discharge. 
The crude mortality rate was 33.2% (556 of 1,677) for patients 
who had contracted at least 1 ICU-acquired NI and 20.0% 
(1,279 of 6,391) for patients without ICU-acquired NI during 
their stay (P<.001). 
Overall, 1,725 case patients were successfully matched to 
1,725 control patients (total n = 3,450) for the final analysis. 
These 1,725 deceased patients represented 94% of all deceased 
subjects from the source population of our study. Case pa-
tients and control patients differed by mean length of stay 
(P = .031), mean Simplified Acute Physiology Score II 
(P< .001), immunocompromised status (P< .001), and type 
of admission conditions (P<.001) (Table 2). During the 
study period, the incidence of ICU-acquired NI was 31.0% 
for case patients and 19.5% for the control patients (P< 
.001). 
Attributable Mortality Due to ICU-Acquired NI 
Table 3 presents crude and adjusted ROD in patients who 
experienced at least 1 ICU-acquired NI. Each model provides 
an estimate of the PAF for ICU mortality that relates to ICU-
acquired NI, stratified by type of infection and the number 
of infected sites. The PAF for each of the 5 models of ICU-
acquired NI is reported in Table 4. The PAF due to ICU-
acquired NI in patients who died before ICU discharge was 
14.6% (95% CI, 14.4%-14.8%), which means that of 100 
deaths that occurred before ICU discharge, 14.6 were related 
to an ICU-acquired NI. Stratified by type of infection, the 
PAFs were 6.1% (95% CI, 5.7%-6.5%) for pulmonary in-
fection, 3.2% (95% CI, 2.8%-3.5%) for CVC infection, and 
1.7% (95% CI, 0.9%-2.5%) for BSI. No significant propor-
tion of deaths was attributable to UTI when it was the pa-
tient's only infected site (PAF, 0.0 [95% CI, -0.4% to 0.4%]). 
Under the assumption of the additive property of the statis-
tical model used, the sum of all infection-specific PAF values 
was equal to the global PAF presented in model l.25"27 
D I S C U S S I O N 
The objective of this study was to estimate the PAF for patient 
deaths due to infection acquired before ICU discharge. The 
3 major findings of this study were as follows: First, 14.6% 
TABLE 2. Entry Characteristics of Case Patients Who Died before 
Dischange and Matched Control Patients Who Survived to Dis-
charge in 11 Intensive Care Units (ICUs) at the University Hospital 
of Lyon, 1995-2003 
Case Control 
patients patients 
Characteristic (n = 1,725) {n = 1,725) P" 
Length of ICU stay, days 9.6 ± 7.1 10.1 ± 7.3 .031 
SAPS II 52.4 ± 18.5 38.5 ± 16.2 <.001 
Immunocompromised 314 (18.2) 258 (15.0) <.001 
Admission condition <c.001 
Medical 435 (25.2) 565 (32.8) 
Surgical 1,079 (62.6) 892 (51.7) 
Trauma 211 (12.2) 268 (15.5) 
NOTE. Values are expressed as no. (%) for qualitative variables and as 
mean ± standard deviation (SD) for quantitative variables. SAPS II, Sim-
plified Acute Physiology Score. 
" The McNemar test was used to compare categorical variables, and the 
paired Student t test was used to compare continuous variables. 
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TABLE 3. Relative Odds of Death (ROD) in Relation to Different Risk Levels of Intensive Care Unit (ICU)-Acquired 
Nosocomial Infections (NIs) using Conditional Logistic Regression Models at 11 Intensive Care Units at the University 
Hospital of Lyon, 1995-2003 
Risk levels of ICU-acquired NI 
Model 1 
No infection 
At least 1 pulmonary infection, CVC infection, UTI, or BSI 
Model 2 
No infection 
Only 1 pulmonary infection 
Pulmonary infection and at least 1 other infected site 
At least 1 other infected site, pulmonary infection excluded 
Model 3 
No infection 
Only 1 CVC infection 
CVC infection and at least 1 other infected site 
At least 1 other infected site, CVC infection excluded 
Model 4 
No infection 
Only 1 UTI 
UTI and at least 1 other infected site 
At least 1 other infected site, UTI excluded 
Model 5 
No infection 
Only 1 BSI 
BSI and at least 1 other infected site 
At least 1 other infected site, BSI excluded 
Crude ROD 
ROR (95% CI) 
1.0 
1.9 (1.6-2.2) 
1.0 
3.1 (2.2-4.20) 
3.3 (2.2-4.7) 
1.4 (1.1-1.6) 
1.0 
1.8 (1.3-2.4) 
2.4 (1.6-3.4) 
1.8 (1.5-2.2) 
1.0 
0.8 (0.6-1.1) 
1.6 (1.1-2.3) 
2.6 (2.1-3.1) 
1.0 
3.5 (1.9-6.8) 
1.9 (1.3-2.9) 
1.8 (1.5-2.1) 
P 
<.001 
<.001 
<.001 
.002 
<.001 
<.001 
<.001 
.205 
.011 
<.001 
<.001 
.001 
<.001 
Adjusted ROD 
ROR (95% CI) 
1.0 
1.9* (2.0-3.1) 
1.0 
3.3 (2.2-4.8) 
3.3 (2.1-5.1) 
1.4 (1.1-1.7) 
1.0 
1.8 (1.3-2.5) 
2.2 (1.4-3.4) 
1.9 (1.5-2.4) 
1.0 
1.0 (0.6-1.3) 
1.9 (1.2-2.9) 
2.5 (1.9-3.2) 
1.0 
3.9 (1.7-8.7) 
2.0 (1.2-3.3) 
1.8 (1.5-2.3) 
P 
<.001 
<.001 
<.001 
<.001 
<.001 
<.001 
<.001 
.598 
<.001 
<.001 
<.001 
<.001 
<.001 
NOTE. Adjusted on Simplified Acute Physiology Score II (SAPS) as categorical variable, immunocompromised status as dichot-
omous variable, and type of admission condition as categorical variable. BSI, bloodstream infection; CI, confidence interval; CVC, 
central venous catheter; ROR, relative odds ratio; UTI, urinary tract infection. 
* The ROD is increased by 1.9 in case patients who experienced at least 1 ICU-acquired NI, compared with case patients who did 
not. 
of deaths (95% CI, 14.4%-14.8%) might be attributed to lower ratio was due to computation of the death attributable 
ICU-acquired NI. Second, to estimate mortality attributable proportion, which was taken into account for the incidence 
to ICU-acquired NI, it may be clinically useful and comple- of exposure for case patients. The incidence of exposure to 
mentary to other, commonly risk-based, methods to use the only pulmonary infection was 8.7%, compared with 15.9% 
PAF concept. Third, exposure to ICU-acquired NI was an for at least 1 infected site, pulmonary infection excluded. This 
important determinant of death in our population. finding is an interesting contribution of this study,30 32 which 
The proportion of deaths attributable to ICU-acquired NI underscores the fact that a difference exists between the risk 
was likely associated with the incidence of exposure to in- for an event to occur (ie, excess risk) and the attributable 
fections rather than with the ROD associated with the level risk for the same event, depending on the incidence of ex-
of infection. Therefore, the incidence of exposure to infections posure to risk factors for that event. In theory, odds is the 
was far more relevant than only the risk of infection by itself. ratio of the probability that an event of interest occurs to the 
Because we analyzed attributable risk, in order to find the probability that it does not occur (in contrast, risk is the 
effect of ICU-acquired NI on mortality, it was more appro- probability for an event to occur within an exposed 
priate to study the effect of incidence of infections than to population),33'34 while an attributable event refers to how 
study the effect of risk of infection. For example, the ratio many events are the direct consequence of an exposure.34 This 
of the ROD of 3.3 for pulmonary infection only (Table 4) to concept has not been adequately explored in the field of hos-
tile ROD of 1.4 for at least 1 infected site, pulmonary infection pital-acquired infections, compared with other public health 
excluded, was 2.4. In contrast, the number of deaths attrib- domains.35"37 
utable only to PI was 6.1% (95% CI, 5.7%-6.5%) and the For clinical practice, these findings could be of major in-
number of deaths attributable to at least 1 infected site, PI terest. Table 4 reports that 14.6% (95% CI, 14.4%-14.8%) 
excluded, was 4.6% (95% CI, 4.3%-4.9%) (Table 4), so the of deaths during ICU stay are attributable to ICU-acquired 
ratio of deaths attributable only to PI to deaths attributable NI, whatever the site of infection. For pulmonary infection 
to at least 1 infected site, PI excluded, was only 1.3. This only or pulmonary infection with a coinfection, the propor-
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TABLE 4. Population-Attributable Fraction (PAF) of Deaths According to Different Risk Levels 
of Intensive Care Unit (ICU)-Acquired Nosocomial Infections (NIs) at 11 ICUs at the University 
Hospital of Lyon, 1995-2003 
Risk level of ICU-acquired NI CF£, % PAF, % (95% CI) 
Model 1 
At least 1 pulmonary infection, CVC infection, UTI, or BSI 
Model 2 
Only 1 pulmonary infection 
Pulmonary infection and at least 1 other infected site 
At least 1 other infected site, pulmonary infection excluded 
Model 3 
Only 1 CVC infection 
CVC infection and at least 1 other infected site 
At least 1 other infected site, CVC infection excluded 
Model 4 
Only 1 UTI 
UTI and at least 1 other infected site 
At least 1 other infected site, UTI excluded 
Model 5 
Only 1 BSI 
BSI and at least 1 other infected site 
At least 1 other infected site, BSI excluded 
31.0 
8.7 
6.4 
15.9 
7.2 
5.3 
18.5 
4.2 
4.1 
22.7 
2.3 
3.8 
24.9 
14.6 (14.4-14.8) 
6.1 (5.7-6.5) 
4.5 (4.0-5.0) 
4.6 (4.3-4.9) 
3.2 (2.8-3.5) 
2.9 (2.4-3.4) 
8.7 (8.4-9.1) 
0.0 (-0.4 to 0.4) 
1.9 (1.4-2.4) 
13.6 (13.3-13.9) 
1.7 (0.9-2.5) 
1.9 (1.4-2.4) 
11.0 (10.8-11.2) 
NOTE. PAF = CF, x [(ROD- O/ROD), where CFE is the case p»tientfr«ction*xpose<i to lCU-ati^uir«l 
NI and [(ROD - l)/ROD] is the etiological fraction of attributable risk for case patients to be exposed at 
least once to ICU-acquired NI. BSI, bloodstream infection; CVC, central venous catheter; UTI, urinary tract 
infection. 
tion of deaths attributable to pulmonary infection was 10.6%. 
For CVC infection only or CVC infection with a coinfec-
tion, the proportion of deaths attributable to CVC infection 
was 6.1%. Interventions to reduce the mortality attributable 
to ICU-acquired NI should be focused on these 2 sites of 
infection because of their high incidence. In particular, be-
cause of their incidence and potential effect on mortality, 
pulmonary infections should be a primary target for inter-
ventions. A recent study has demonstrated that prevention 
of ventilator-associated pneumonia by means of selective di-
gestive tract decontamination and selective oropharyngeal de-
contamination can reduce ICU and 28-day mortality, com-
pared with no intervention.38 Additional and less controversial 
preventive measures to decrease exogenous or endogenous 
cross-transmission to prevent ventilator-associated pneumonia 
should be considered. For instance, increased compliance with 
hand hygiene, short duration of intubation, nonprofound se-
dation, and correct patient positioning may help to decrease 
rates of ventilator-associated pneumonia rates and ultimately 
to decrease the likelihood of death. 
For decades, the method chosen for this study has been 
used in chronic disease epidemiology to examine attributable 
mortality. Conceptually, we assumed that the ROD was dif-
ferent from the total number of deaths related to an exposure, 
allowing estimation of the "etiological fraction," as proposed 
by Samore and Harbarfh.39 The advantage of our method of 
calculating the PAF is that it takes into account multiple levels 
of exposure (pulmonary infection, CVC infection, UTI, and 
BSI). This stems from the PAF concept developed by Levin 
in 1953:40 when risk is multilevel (at least 2 categories), con-
founders are present, and risk adjustment is needed.26,27 
Some limitations must be addressed. For each patient, only 
the first infection by site was considered for analysis. More-
over, the cumulative effect of repeated infections was not 
estimated. The analysis was not stratified by the causative 
microorganisms responsible for the infection. It was not pos-
sible to match or adjust for the causative organisms because 
infections were frequently polymicrobial. However, a similar 
study design could be used for patients infected by a specific 
microorganism of high clinical interest (eg, Staphylococcus 
aureus or Pseudomonas aeruginosa). In future studies, analysis 
stratified by microorganism might be helpful to identify the 
pathogens that are associated with the worst prognosis.4143 
Since our estimate of ROD is closer to an odds ratio than to 
a relative risk, the strength of association could have been 
overestimated. In addition, the lower incidence of death in 
the population that was excluded from the analysis because 
of missing data on ICU-acquired NI (JV = 4,178) could have 
biased our results. In consequence, the true proportion of 
attributable deaths due to ICU-acquired NI might be lower 
than in our results. Finally, residual confounding factors can-
not be excluded, owing to the design of the surveillance net-
work, since data were collected prospectively for surveillance 
of ICU-acquired NI and not primarily for survival analysis. 
C O N C L U S I O N S 
In summary, the results of this study strongly suggest that an 
important proportion of ICU deaths was caused by NI. These 
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results support previous evidence that death and ICU-ac-
quired NI are causally linked, but the strength of the asso-
ciation may vary according to the methodological approach 
taken. The method reported in this study could be considered 
complex because it has not often been used in the field; 
however, the use of this method can yield additional results 
to illuminate a controversial issue. The incidence of exposure 
was a major determinant identified by use of our method. 
Therefore, one way to estimate the contribution of ICU-ac-
quired NI to mortality might be based on estimation of the 
PAF, which takes into account the incidence of exposure to 
ICU-acquired NI. 
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A P P E N D I X 
TABLE A. Five Models, Stratified by Type of Nosocomial Infections (NIs) Acquired in the Intensive Care 
Unit (ICU) and Risk Levels 
Risk level Definition 
Model 1: ICU-acquired pulmonary infection, 
CVC infection, UTI, and/or BSI 
0 
1 
Model 2: ICU-acquired pulmonary infection 
0 
1 
2 
3 
Model 3: ICU-acquired CVC infection 
0 
1 
2 • 
3 
Model 4: ICU-acquired UTI 
0 
1 
2 
3 
Model 5: ICU-acquired BSI 
0 
1 
2 
3 
No infection 
At least 1 pulmonary infection, CVC infection, UTI, or BSI 
No infection 
Only 1 pulmonary infection 
Pulmonary infection and at least 1 other infected site 
At least 1 other infected site, pulmonary infection excluded 
No infection 
Only 1 CVC infection 
CVC infection and at least 1 other infected site 
At least 1 other infected site, CVC infection excluded 
No infection 
Only 1 UTI 
UTI and at least 1 other infected site 
At least 1 other infected site, UTI excluded 
No infection 
Only 1 BSI 
BSI and at least 1 other infected site 
At least 1 other infected site, BSI excluded 
N O T E . BSI, bloodstream infection; CVC, central venous catheter; UTI, urinary tract infection. 
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